FTH

SEC source: 0002111813-26-000008 · form4a-06162026_080634.xml · derivative · entry 3

Parikh Anand Kiran · CIK 0002111813 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,884

Underlying: Common Stock · 136,884 shares

Expires 2025-11-30

F6 · kind: Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.

F6 · price: Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.

F7 · derivative.exercise_date: Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027.

SEC source: 0002111813-26-000008 · form4a-06162026_080634.xml · derivative · entry 2

Parikh Anand Kiran · CIK 0002111813 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,320

Underlying: Common Stock · 12,320 shares

Expires 2032-09-14

F4 · kind: Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.

F4 · price: Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.

F5 · derivative.exercise_date: Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0002111813-26-000008 · form4a-06162026_080634.xml · derivative · entry 1

Parikh Anand Kiran · CIK 0002111813 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 761,428

Underlying: Common Stock · 761,428 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the "Company"). The Preferred Stock has no expiration date.

F2 · kind: Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. ("HoldCo") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the "Merger Agreement"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth").

F3 · kind: Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock ("Common Stock").

F2 · price: Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. ("HoldCo") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the "Merger Agreement"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth").

F3 · price: Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock ("Common Stock").

F1 · derivative.exercise_date: Each share of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the "Company"). The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the "Company"). The Preferred Stock has no expiration date.

SEC source: 0001238120-26-000004 · form4-02172026_100221.xml · derivative · entry 1

Donenberg Phillip B. · CIK 0001238120 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,900

Underlying: Common Stock · 1,900 shares

Expires 2036-02-12

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or February 13, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0000897069-25-001795 · form4.xml · derivative · entry 6

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 395 shares

Expires 2035-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.

F6 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 5

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,142

F4 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.91 to $7.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 4

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,588

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 3

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,588

F3 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.80 to $8.33. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,254

F1 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.50 to $9.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001793 · form4.xml · derivative · entry 6

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 395 shares

Expires 2035-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.

F6 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0000897069-25-001793 · form4.xml · nonDerivative · entry 5

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 155,142

F4 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.91 to $7.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001793 · form4.xml · nonDerivative · entry 4

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 155,588

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001793 · form4.xml · nonDerivative · entry 3

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 155,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001793 · form4.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 155,588

F3 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.80 to $8.33. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001793 · form4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 158,254

F1 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.50 to $9.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 4

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,359

F6 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $13.00 to $13.26. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 3

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,401

F5 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $12.02 to $12.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,146

F4 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $11.00 to $12.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001774 · form4.xml · nonDerivative · entry 4

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 161,359

F6 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $13.00 to $13.26. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001774 · form4.xml · nonDerivative · entry 3

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 161,401

F5 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $12.02 to $12.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001774 · form4.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 163,146

F4 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $11.00 to $12.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,654

F1 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.00 to $9.54. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001774 · form4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · 10% owner · See remarks below

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 177,654

F1 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.00 to $9.54. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.

F3 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001415889-25-014485 · form4-05232025_040514.xml · derivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-25-014484 · form4-05232025_040512.xml · derivative · entry 1

RICKS THOMAS G · CIK 0001013023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-25-014483 · form4-05232025_040509.xml · derivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F2 · ownership.nature: These options are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the options, and shares exercisable thereunder, held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such options.

SEC source: 0001415889-25-014482 · form4-05232025_040506.xml · derivative · entry 1

Humer Kristian · CIK 0001872280 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-25-014481 · form4-05232025_040503.xml · derivative · entry 1

Holmen Bob · CIK 0001843508 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-25-014480 · form4-05232025_040501.xml · derivative · entry 1

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-25-005728 · form4-02262025_110226.xml · nonDerivative · entry 1

Celebi John · CIK 0001843539 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,862

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2024 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001415889-25-005727 · form4-02262025_110225.xml · nonDerivative · entry 1

van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,794

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2024 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001415889-25-004229 · form4-02142025_110206.xml · derivative · entry 1

Krebs Stephanie · CIK 0001998150 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001415889-25-004226 · form4-02142025_110254.xml · derivative · entry 1

Craver Josiah · CIK 0002038400 · Principal Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001415889-25-004223 · form4-02142025_110236.xml · derivative · entry 1

Celebi John · CIK 0001843539 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001415889-25-004222 · form4-02142025_110252.xml · derivative · entry 1

van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001415889-24-030070 · form4-12232024_041229.xml · derivative · entry 1

Krebs Stephanie · CIK 0001998150 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2034-12-19

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date.

SEC source: 0001415889-24-030069 · form4-12232024_041227.xml · derivative · entry 1

van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-12-19

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date.

SEC source: 0001415889-24-030068 · form4-12232024_041225.xml · derivative · entry 1

Craver Josiah · CIK 0002038400 · Principal Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-12-19

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date.

SEC source: 0001415889-24-030067 · form4-12232024_041224.xml · derivative · entry 1

Celebi John · CIK 0001843539 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,000

Underlying: Common Stock · 355,000 shares

Expires 2034-12-19

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date.

SEC source: 0001415889-24-016699 · form4-06132024_090650.xml · derivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-016698 · form4-06132024_090616.xml · derivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F2 · ownership.nature: These options are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the options, and shares exercisable thereunder, held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such options.

SEC source: 0001415889-24-016696 · form4-06132024_090618.xml · derivative · entry 1

Holmen Bob · CIK 0001843508 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-016694 · form4-06132024_090614.xml · derivative · entry 1

English Jessie · CIK 0001854515 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-016693 · form4-06132024_090600.xml · derivative · entry 1

Humer Kristian · CIK 0001872280 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-016692 · form4-06132024_090645.xml · derivative · entry 1

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-016691 · form4-06132024_090627.xml · derivative · entry 1

RICKS THOMAS G · CIK 0001013023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-016689 · form4-06132024_090608.xml · derivative · entry 1

Vojta Deneen · CIK 0001843509 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-004236 · form4-02162024_110255.xml · derivative · entry 3

van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,102

Underlying: Common Stock · 90,102 shares

Expires 2034-02-14

F4 · derivative.exercise_date: Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.

SEC source: 0001415889-24-004236 · form4-02162024_110255.xml · derivative · entry 2

van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2034-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.